Eli Lilly has announced that a late-stage trial of its investigative candidate, donanemab, significantly slowed the cognitive and functional decline in people with early symptomatic Alzheimer's disease. …
Lilly's investigative Alzheimer’s treatment slowed disease progression in late-stage trial
May 4, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
New report highlights widening gap in access to modern medicines between Australia and NZ
October 8, 2025 - - Latest News -
RACGP warns of mounting pressure on GPs as costs and complexity rise
October 7, 2025 - - Other Health -
AusBiotech’s annual report highlights a defining year for Australia’s life sciences sector
October 7, 2025 - - Australian Biotech -
AstraZeneca becomes the latest to say it could halt UK investment over 'appalling' pricing regime
October 7, 2025 - - Latest News -
MTPConnect and Wholesale Investor unite to accelerate investment in life sciences sector
October 7, 2025 - - Australian Biotech -
Percheron Therapeutics reports positive final data from early-phase trial of HMBD-002
October 7, 2025 - - Australian Biotech -
FDA clears clinical hold on Neurizon's NUZ-001, paving way for HEALEY ALS trial
October 7, 2025 - - Australian Biotech